{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Sample+Collection&page=6", "query": { "intervention": "Serum Sample Collection", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 562, "total_pages": 57, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Sample+Collection&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Sample+Collection&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T09:39:53.050Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06572618", "title": "Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Positron Emission Tomography and Computed Tomography Scan", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-01-22", "completion_date": "2027-01-08", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06572618" }, { "nct_id": "NCT06498635", "title": "Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2025-04-01", "completion_date": "2039-07-15", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 280, "location_summary": "Jonesboro, Arkansas • Beverly Hills, California • Dublin, California + 223 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06498635" }, { "nct_id": "NCT01896999", "title": "Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 146, "start_date": "2014-03-07", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 479, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896999" }, { "nct_id": "NCT04423198", "title": "HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mild Traumatic Brain Injury" ], "interventions": [ { "name": "Cognitive Assessment", "type": "BEHAVIORAL" }, { "name": "Patient Reported Neurological Outcome Assessments", "type": "BEHAVIORAL" }, { "name": "Blood Draw", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE" ], "sponsor": "BRAINBox Solutions Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2020-12-31", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-08-04", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 11, "location_summary": "Kansas City, Kansas • Detroit, Michigan • Rochester, New York + 5 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04423198" }, { "nct_id": "NCT05976763", "title": "Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Esophagogastroduodenoscopy", "type": "PROCEDURE" }, { "name": "Colonoscopy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 421, "start_date": "2023-10-20", "completion_date": "2038-08-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 238, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05976763" }, { "nct_id": "NCT05821088", "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tafasitamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2023-06-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05821088" }, { "nct_id": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib Fumarate", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 1400, "start_date": "2020-07-21", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04293562" }, { "nct_id": "NCT03868202", "title": "Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicle Stimulating Hormone Glycosylation", "Urinary FSH21/FSH24 Ratio", "Estradiol Effect" ], "interventions": [ { "name": "Estradiol Transdermal Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Virginia Medical School", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "20 Years to 55 Years · Female only" }, "enrollment_count": 10, "start_date": "2019-07-03", "completion_date": "2020-01", "has_results": false, "last_update_posted_date": "2019-07-12", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03868202" }, { "nct_id": "NCT01812239", "title": "Vaginal Progesterone in Twins With Short Cervix", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Premature Birth" ], "interventions": [ { "name": "Vaginal Progesterone gel.", "type": "DRUG" }, { "name": "fetal fibronectin swab.", "type": "PROCEDURE" }, { "name": "Placebo gel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Obstetrix Medical Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 0, "start_date": "2014-03", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 1, "location_summary": "San Jose, California", "locations": [ { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01812239" }, { "nct_id": "NCT04981509", "title": "Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hereditary Leiomyomatosis and Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Renal Cell Carcinoma", "Sporadic Papillary Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sodium Fluoride F-18", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 65, "start_date": "2022-06-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-18T09:39:53.050Z", "location_count": 13, "location_summary": "La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04981509" } ] }